A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials by Simes, John et al.
A Novel Method to Adjust Efficacy Estimates for Uptake
of Other Active Treatments in Long-Term Clinical Trials
John Simes
1*, Merryn Voysey
1, Rachel O’Connell
1, Paul Glasziou
2, James D. Best
3, Russell Scott
4,
Christopher Pardy
1, Karen Byth
1, David R. Sullivan
5, Christian Ehnholm
6, Anthony Keech
1, for the FIELD
Study Investigators
1National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia, 2Centre for Evidence-Based Medicine, University of Oxford,
Oxford, United Kingdom, 3Faculty of Medicine, University of Melbourne, Melbourne, Australia, 4Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch,
New Zealand, 5Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Sydney, Australia, 6Biomedicum Helsinki, National Public Health Institutes, Helsinki,
Finland
Abstract
Background: When rates of uptake of other drugs differ between treatment arms in long-term trials, the true benefit or
harm of the treatment may be underestimated. Methods to allow for such contamination have often been limited by failing
to preserve the randomization comparisons. In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study,
patients were randomized to fenofibrate or placebo, but during the trial many started additional drugs, particularly statins,
more so in the placebo group. The effects of fenofibrate estimated by intention-to-treat were likely to have been
attenuated. We aimed to quantify this effect and to develop a method for use in other long-term trials.
Methodology/Principal Findings: We applied efficacies of statins and other cardiovascular drugs from meta-analyses of
randomized trials to adjust the effect of fenofibrate in a penalized Cox model. We assumed that future cardiovascular
disease events were reduced by an average of 24% by statins, and 20% by a first other major cardiovascular drug. We
applied these estimates to each patient who took these drugs for the period they were on them. We also adjusted the
analysis by the rate of discontinuing fenofibrate. Among 4,900 placebo patients, average statin use was 16% over five years.
Among 4,895 assigned fenofibrate, statin use was 8% and nonuse of fenofibrate was 10%. In placebo patients, use of
cardiovascular drugs was 1% to 3% higher. Before adjustment, fenofibrate was associated with an 11% reduction in
coronary events (coronary heart disease death or myocardial infarction) (P=0.16) and an 11% reduction in cardiovascular
disease events (P=0.04). After adjustment, the effects of fenofibrate on coronary events and cardiovascular disease events
were 16% (P=0.06) and 15% (P=0.008), respectively.
Conclusions/Significance: This novel application of a penalized Cox model for adjustment of a trial estimate of treatment
efficacy incorporates evidence-based estimates for other therapies, preserves comparisons between the randomized
groups, and is applicable to other long-term trials. In the FIELD study example, the effects of fenofibrate on the risks of
coronary heart disease and cardiovascular disease events were underestimated by up to one-third in the original analysis.
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Introduction
A common problem in longer-term clinical trials comparing
chronic treatments is that patients may start using additional active
therapies during the course of the trial, which may confound the
evaluation of the trial’s target treatments [1,2]. This is particularly
the case when the uptake of such therapies differs between the
treatment arms, potentially resulting in an underestimation of the
direct benefit of the target treatment. Additional therapies may be
given to patients as a result of new evidence emerging from other
ongoing trials or because of changes in patient and clinician choice
over time, and also to those responding poorly to initial
treatments, as in some cancer trials [3]. Patients may discontinue
trial treatments for similar reasons.
Conventional methods in clinical trials either use intention-to-
treat analysis only or adjust for changes in treatment after
randomization (such as in per-protocol analyses). The former
may underestimate the true biological effect of treatment because
of noncompliance, and the latter may be confounded by the
differences between those patients who do and those who do not
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and those who do not take up other therapies. These latter
analyses are prone to selection bias, in that they do not maintain
the randomized structure of the comparisons [1,4,5].
This specific problem arose in the analysis of the 5-year
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)
trial — a large-scale trial of the lipid-modifying effects of fenofibrate
compared with placebo in patients with type 2 diabetes mellitus [6].
The study design was pragmatic in evaluating the effect of
fenofibrate on a background of usual medical care [6,7]. This
meant that in the light of new clinical circumstances or the
emergence of new evidence, additional cardiovascular medicines,
including statins and other lipid modifying treatments, could be
commenced during the course of the trial. Methods have been
proposed to account for noncompliancewith randomized treatment
[1,8] (including instrumental variable analysis [9–11]), but these
methods do not deal with the situation we encountered in FIELD of
a large imbalance between the treatment groups in the proportion
ofpatientswhocommencedactivenonstudymedications.Inthestandard
intention-to-treat analysis, unbalanced uptake of nonstudy treat-
ment can attenuate the estimated effect of the study drug.
Measuring the influence of the uptake of nonstudy medications
requires estimates of the effect of these medications from sources
external to the trial in question [1], as any estimates derived from
within the trial are subject to selection bias. In this analysis, using
FIELD as our example, we report a novel method for incorporating
external evidence-based estimates to correct for this.
Adjustment for any dilution of the treatment effect caused by
discontinuation of the randomized study drug by some patients
was also examined by using a randomization-based efficacy
estimator to adjust for nonadherence to study treatment [1].
Methods
FIELD Trial Design
FIELD was a randomized double-blind placebo-controlled trial
in 9795 middle-aged to elderly people with type 2 diabetes mellitus
[6,7,12] After a 16-week run-in period, patients wererandomized to
micronised fenofibrate (200 mg daily) or matching placebo and
followed up through regular clinic visits in addition to usual care
fromtheirtreatingdoctorsforaplanned mediandurationof5years.
During the course of the trial and before any unblinding of
results, the trial’s progress was monitored for rates of commence-
ment of open-label lipid treatment, adherence to study treatment,
and cardiovascular events (for both treatment groups combined). In
the light of emerging evidence of the effectiveness of statin therapy,
theincreaseduptakeofstatintreatmentinthe trial,anda lowerthan
expected pooled event rate, the primary outcome, coronary heart
disease (CHD) death, was revised in 2002 to CHD events (CHD
death or myocardial infarction) [6]. The revised trial design was
powered to detect a 22% reduction in CHD events (based on
intention-to-treat analysis). This corresponded to a 27% reduction
among those on treatment (based on a per-protocol analysis).
Patient Population and Treatments
Patients with diabetes, with or without pre-existing cardiovas-
cular disease or lipid abnormalities, were eligible, provided total
blood cholesterol level at screening was 3.0 to 6.5 mmol/L, and
either the triglyceride level was between 1.0 and 5.0 mmol/L or
the total cholesterol/high-density lipoprotein cholesterol ratio was
4.0 or higher. Lipid values at screening were provided to the
patients’ doctors before randomization: all patients for whom any
cholesterol-lowering treatment (including statins) was indicated at
the start of the trial were ineligible. However, these (and other)
medications could be commenced after randomization if the usual
doctor considered it appropriate (for example, because of changed
clinical circumstances) [12].
Cardiovascular medications were recorded at each follow-up
visit (at least 6 monthly), as was adherence to study treatment.
Cardiovascular Outcomes and Subgroups
The primary study endpoint was the first occurrence of CHD
death or nonfatal myocardial infarction. Secondary outcomes
included major cardiovascular events (CHD events, total stroke
and other cardiovascular death combined), total cardiovascular
events (major cardiovascular events plus coronary and carotid
revascularization), CHD death, total cardiovascular deaths, stroke,
and coronary and peripheral revascularization procedures.
The adjusted effect of fenofibrate on total cardiovascular events
was examined within the main subgroups — men vs women, those
aged ,65 years vs those aged $65 years, and the presence vs
absence ofpriorcardiovasculardisease— toseewhetherdifferential
uptake of other medicines by subgroup affected these comparisons.
Estimates of Treatment Effect of Statins and Other
Cardiovascular Drugs
The effectiveness of various medications in preventing cardio-
vascular events has been well established in several randomized
controlled trials (Table S1) [13–20], with estimates of reductions in
events in various settings ranging from 16% to 63%. The effect of
combinations of drugs has, for the most part, been observed to be
multiplicative on the basis of a similar relative risk reduction in
randomized trials in the presence or absence of other drugs [14,21].
In this analysis, evidence for the effectiveness of statins and other
cardiovascular medicineswasbasedonpublishedsystematicreviews
of randomized trials of these therapies for diabetes populations and,
in the absence of heterogeneity of treatment effects, for broader
populations at risk of cardiovascular disease. Effects of the following
medicines or classes of drugs were used in the adjusted analyses:
statin drugs (simvastin, atorvastatin, pravastastin, any other statin);
angiotensin-converting enzyme (ACE) inhibitors or angiotensin II
receptor blockers; beta blockers; calcium-channel antagonists;
diuretics; antiplatelet drugs (aspirin or other).
The estimate of the effect of statin use on subsequent
cardiovascular events was based on the estimate of the Cholesterol
Treatment Trialists’ Collaboration’s (CTTC) systematic overview
of 14 large-scale randomized trials of statin therapy: a 21%
reduction in cardiovascular events per mmol/L reduction in low-
density lipoprotein (LDL) cholesterol [22]. Subgroup meta-analysis
showed no heterogeneity of the statin treatment effect between
those with and those without diabetes [23].
We estimated the absolute reduction in LDL cholesterol by
statin therapy by applying the average percentage reduction in
LDL cholesterol, estimated from a meta-analysis of 164 short-term
randomized trials [24], to the LDL cholesterol levels of each
treatment group (fenofibrate or placebo) in our cohort before they
started any statin therapy. This average percentage reduction in
LDL cholesterol was weighted according to the different statin
drugs taken and the average dose of each used within each
treatment group. The assumed event reduction (for each type of
event) was then determined as the relative reduction in events per
mmol/L reduction in LDL cholesterol multiplied by the average
absolute reduction in LDL cholesterol.
For other cardiovascular drugs (ACE inhibitors, beta blockers,
calcium-channel blockers, diuretics and antiplatelet drugs), a more
simple, yet conservative, approach was taken. There was an
assumed 20% reduction in the risk of any subsequent cardiovas-
Improved Efficacy Estimates
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reduction for each additional drug.
Statistical Methods
All patients were included in the randomized comparisons, and
analyses were by intention-to-treat. As specified in the published study
protocol, the unadjusted primary analyses for cardiovascular events
used standard log–rank methods without adjustment for covariates
[25], and Cox proportional-hazards modelling was used to compute
hazard ratios (HRs) and their 95% confidence intervals [26,27].
Adjustment for the use of other cardiovascular medications used
a penalized Cox model [27], for which the general formula for the
hazard function at time t for patient i is:
li t ðÞ ~l0 t ðÞ eXibzZi t ðÞ v
where l0(t) is the baseline hazard function, Xi is the covariate
indicator for treatment group (=1 for fenofibrate and 0 for
placebo) and Zi(t) is the covariate vector indicating usage of
cardiovascular disease medicines at time t for patient i. In this
model b is the parameter for the treatment effect of fenofibrate
(unconstrained coefficient), while v is a vector of the assumed
effects of other cardiovascular disease medicines (constrained
coefficients). The HR from this model for the adjusted fenofibrate
effect is estimated as exp (b
‘).
When we adjusted for the effect of statins only, the constrained
coefficient v (offset) in this formula was set to the log of the HR for
the effect of statin therapy within the treatment group. For example,
the evidence-based effect of statins on total cardiovascular events
was estimated to be 25%in those on placebo, and thus for a placebo
patient, v=log(0.75). In the case of adjustment for other
cardiovascular medications, the value of the offset was calculated
on the basis of the number and type of medicines taken by each
patient at any time (20% reduction in risk from the first additional
drug taken and a 15% reduction for each additional drug). The
Table 1. Use of the study drug and other medication (average % over 5 years) by treatment group and major subgroup in the
FIELD study (n=9795).
Discontinuedstudy drug Discontinued study drug
Started other lipid-
lowering treatment*
Started other lipid-
lowering treatment*
Subgroup % Placebo group Fenofibrate group Placebo group Fenofibrate group
Sex
Men 63 9 10 17 9
Women 37 10 11 18 7
Age (years)
,65 60 9 9 17 8
$65 40 10 12 18 9
Previous CVD
Yes 22 11 14 23 14
No 78 9 9 16 7
Hypertension
Yes 84 9 10 17 9
No 16 10 10 16 7
Waist measurement
High{ 68 10 10 17 9
Low 32 9 11 17 7
Dyslipidemia
Yes{ 38 10 12 21 12
No 62 9 10 15 6
HDL cholesterol (mmol/L)
High 41 9 9 15 6
Low1 59 10 11 19 10
LDL cholesterol (mmol/L)
,3.0 45 9 11 11 6
3.0–3.5 29 9 10 17 9
.3.5 mmol/L 26 11 11 28 11
All patients 100 10 10 17 8
*Based on patients who took statins, resins, fibrates or other lipid-modifying drugs for at least 3 months.
{Men: $102 cm; women: $88 cm.
{Low HDL cholesterol plus high triglyceride ($1.7 mmol/L).
1,1.03 mmol/L for men, ,1.29 mmol/L for women.
FIELD=Fenofibrate Intervention and Event Lowering in Diabetes; CVD=cardiovascular disease; HDL=high-density lipoprotein; LDL=low-density lipoprotein.
doi:10.1371/journal.pone.0008580.t001
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statins), if the patient was treated with statins, plus log(0.8) for the
first additional drug plus log(0.85) for each subsequent drug. This
value changed as the patient’s prescriptions changed. For example,
a patienttakingastatin,anACEinhibitorand adiureticwouldhave
an offset value of –0.673 (log (0.7560.860.85)) only for the period
he or she was on this combination of therapies.
The efficacy of fenofibrate in a fully adherent group was
estimated, using randomization-based efficacy estimators or
instrumental variable analysis, [1,10] by adjusting for the nonuse
of fenofibrate by the following approximation method:
1{HRadj~ 1{HR ðÞ
.
1{DF ðÞ li t ðÞ ~l0 t ðÞ eXibzZi t ðÞ v
where HRadj is the adjusted HR estimate, HR the unadjusted
estimated HR, and DF the proportion of patients discontinuing
fenofibrate therapy averaged over the study period [28,29]. An
alternative version of this adjustment was undertaken in which DF
was the average proportion discontinuing fenofibrate among
patients having an event [1]. To avoid potential bias due to
treatment decisions that might have been related to the event itself,
we excluded from these calculations data from patients starting
cardiovascular drugs within 1 month of the event.
All results were unadjusted for multiple comparisons. All
analyses used SAS (version 9.1; SAS Institute, Inc. Cary, NC).
Results
Patient Characteristics and Use of Lipid-Modifying
Therapies
Patient characteristics are shown in Table 1. Lipid-lowering
therapy was commenced more often in the group assigned placebo
than the group assigned fenofibrate (average use 17% vs 8%;
P,0.001) and more often among the groups with prior
cardiovascular disease, dyslipidemia or higher baseline LDL
cholesterol levels (each P,0.001). The most common lipid-
lowering therapy used was a statin (in 93% of patients), followed
by a fibrate (6%), and other (2%).
The discontinuation rate of study medication was similar in both
randomized groups, steadily increased over time, and averaged 10%
over the follow-up period of 5 years (Table 1 and Figure 1). The rate
of discontinuation wassomewhat higherthan average among patients
with prior cardiovascular disease or older age, but was similar for
other major groupings. The discontinuation rate among those
subsequently having a cardiovascular event was 8.7% in those
assigned to placebo and 13.9% in those assigned to fenofibrate.
Risk Factors for the Use of Lipid-Modifying Therapies
In a multivariable analysis of baseline risk factors in the placebo
group, higher LDL cholesterol, lower high-density lipoprotein
cholesterol, higher systolic blood pressure, lack of obesity, a
previous CHD event, and country (Australia or New Zealand)
each independently predicted a higher rate of commencing lipid-
lowering therapy, particularly statins (Table 2). When classified
according to a risk score for commencing lipid-lowering therapy,
those patients with the highest scores had a significantly higher
event rate than those with the lowest scores, indicating that
patients at higher risk of cardiovascular disease events were much
more likely to start statin therapy (Table S2).
Use of Statin Therapy and Evidence of Reduction in
Cardiovascular Disease Events
Among patients starting statin therapy, simvastatin and
atorvastatin were most used (Table 3). On the basis of the meta-
analysis by Law et al. [24] and the average daily dosage of statin,
the percentage reduction in LDL cholesterol (average for both
groups) was estimated as 44%, 33%, and 27% for those on
atorvastatin, simvastatin and pravastatin, respectively. Among
those who started statin therapy, the average LDL cholesterol
before starting therapy was 3.31 mmol/L in the placebo group
and 3.04 mmol/L in the fenofibrate group; the average absolute
reductions in LDL cholesterol were estimated at 1.18 and
1.09 mmol/L, respectively.
The assumed effects of statin therapy on subsequent cardiovas-
cular events were estimated as 27% and 25% reductions in CHD
events and 25% and 23% reductions in cardiovascular events in
Figure 1. Time to discontinuing study medication or to starting other lipid-lowering treatment, by randomized group.
doi:10.1371/journal.pone.0008580.g001
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similar estimates were obtained when we applied the results from
the CTTC overview of statin therapy for patients with diabetes
[23] in a sensitivity analysis.
Use of Other Cardiovascular Medicines and Evidence
from Randomized Trials of Cardiovascular Event
Reduction
Use of other cardiovascular drugs was well balanced between
treatment arms at baseline (Table 5). These treatments increased
over the course of the trial. By the close of the study, antiplatelet
therapy was used by half the patients. Use of ACE inhibitors,
beta-blockers and diuretics was slightly more common among
patients assigned placebo than those assigned fenofibrate (each
P,0.05).
Effect of Fenofibrate on Cardiovascular Disease Events
Before any adjustment for other drugs, fenofibrate was
associated with a significant 11% relative risk reduction in total
cardiovascular disease events (P=0.04) and a nonsignificant
11% reduction in the primary outcome, CHD events (P=0.2)
(Table 6, Figure 2). After adjustment for the effect of statin
therapy and other medicines on subsequent cardiovascular
disease events, the effect of fenofibrate was moderately larger
(Table 6). After the additional adjustment for discontinuation of
fenofibrate therapy, efficacy estimates moderately improved to a
15% reduction in cardiovascular events (P=0.008) and a 16%
r e d u c t i o ni nC H De v e n t s( P=0.06). About two-thirds of the
change in effect due to adjustment for other medicines can be
explained by statin use alone (Figure 2). After adjustment for the
use of other medicines and discontinuation of fenofibrate, the
effect of fenofibrate on nonfatal myocardial infarction increased
from 24% to 30%, on stroke from 10% to 14%, and on
revascularization from 20% to 25%. The previously reported
nonsignificant increase in cardiovascular disease deaths was
reduced from 11% to 8%.
In a sensitivity analysis using the approach suggested by White
[1] (using the discontinuation rate only among those having an
event), the fully adjusted estimates of the effect of fenofibrate were
a 16% reduction in cardiovascular events and a 17% reduction in
CHD events.
Table 2. Risk factors for starting lipid-lowering therapy during the FIELD study.*
Risk factor % of 4900 patients* % using lipid-lowering therapy{ Adjusted HR (95% CI){ P
Country ,0.001
Finland 14 18 1.00
Australia 62 36 2.03 (1.68–2.44)
New Zealand 24 48 2.25 (1.85–2.75)
Clinical history
Prior myocardial infarction 5.2 51 1.50 (1.23–1.83) ,0.001
Prior angina 12 47 1.43 (1.24–1.66) ,0.001
Prior PTCA 1.3 57 1.58 (1.12–2.23) 0.01
BMI$30 kg/m
2 48 35 0.91 (0.83–1.00) 0.04
Systolic blood pressure (mm Hg) 0.003
#130 27 35 1.00
.130–140 25 36 1.14 (1.00–1.30)
.140–150 24 38 1.22 (1.07–1.39)
.150 24 37 1.27 (1.11–1.45)
LDL cholesterol (mmol/L) ,0.001
,2.52 20 18 1.00
2.52–,2.91 20 28 1.62 (1.34–1.96)
2.91–,3.25 20 36 2.21 (1.84–2.65)
3.25–,3.63 20 42 2.63 (2.20–3.14)
$3.63 20 57 4.23 (3.56–5.03)
HDL cholesterol (mmol/L) ,0.001
,0.88 20 39 1.00
0.88–,1.005 20 40 0.95 (0.83–1.10)
1.005–,1.125 20 34 0.73 (0.63–0.84)
1.125–,1.285 20 35 0.75 (0.65–0.87)
$1.285 20 34 0.78 (0.67–0.91)
*Model derived by using the placebo group only.
{Patients who had started using statins, fibrates, resins or other lipid-lowering medications during the trial and had remained on them for at least 3 months in total.
{The initial variables were: sex, age, country, clinical history (myocardial infarction, stroke, angina, CABG, PTCA), smoking status, BMI, waist–hip ratio, systolic blood
pressure, diastolic blood pressure, LDL cholesterol, HDL cholesterol, triglyceride.
FIELD=Fenofibrate Intervention and Event Lowering in Diabetes; HR=hazard ratio; CI=confidence interval; PTCA=percutaneous transluminal coronary angioplasty;
BMI=body mass index; HDL=high-density lipoprotein; LDL=low-density lipoprotein.
doi:10.1371/journal.pone.0008580.t002
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Treatment effects within major subgroups are shown in Figure 3
and Table S2. As previously reported, the treatment effect of
fenofibrate was apparently larger among patients without prior
cardiovascular disease than those with, and among patients aged
under 65 years than those aged at least 65 years, as demonstrated
by the interaction P values. Such tests for heterogeneity were
nominally statistically significant, but only when not adjusted for
the multiple subgroup comparisons. The apparent heterogeneity
remained similar after adjustment for the differential use of statins
and other cardiovascular medicines, but these differences became
less significant when other baseline covariates were also adjusted
for. Within each subgroup, the HRs became somewhat lower,
reflecting the greater effect of fenofibrate after adjustment. There
was no consistent pattern of a fenofibrate effect on cardiovascular
events by quintile of risk of statin use, either before or after
adjustment for use of other medicines (Table S2).
Discussion
Our method for adjusting a trial result for other active
treatments is novel. It extends established methods by adjusting
for use of nonstudy medication in a fashion that is not subject to
selection bias. As such, this can be thought of as an adjusted
intention-to-treat analysis, which better determines the underlying
true effect of the study treatment and also estimates an effect for a
fully adherent patient group, while avoiding the biases inherent in
a per-protocol analysis. In the example of the FIELD study, the
likely true effects of treatment were underestimated by more than
one-third in the original simple intention-to-treat analysis.
Conventional methods to adjust for both nonadherence and
nonstudy treatments after randomization have been subject to
selection bias [1,4,5] and higher false-positive rates. Apparent
differences in outcomes may be driven by selection of patients for
inclusion in analysis, rather than by treatment effects.
Methods that adjust the intention-to-treat analyses according to
rates of noncompliance and other factors — randomized-based
efficacy estimation methods — avoid selection bias by basing the
analyses on the original groups [1,3,8–11,28–32]. Approaches to
date have largely been restricted to adjustment for the use or
nonuse of the trial medicines. In particular, instrumental variable
analysis [1,9–11] can estimate average treatment efficacy among
compliers, or among all patients under the assumption of full
adherence to randomized treatment. Estimates are valid under
such an assumption, but, unlike those from per-protocol analyses,
do not account for drop-outs being sicker or healthier than those
continuing on medication, and these methods do not address the
uptake on nonstudy medicines. We adopted a simplified form of this
approach for adjusting for the discontinuation of fenofibrate.
Our method of adjustment for use of nonstudy medicines —
applying external randomized trial evidence for these drugs —uses
a randomization-based efficacy estimate that is not subject to
selection bias. The method applies the same relative risk reduction
(as estimated in other randomized trials) to all patients after they
Table 3. Average use of statins in FIELD and assumed effects on subsequent LDL cholesterol.
Drug Treatment group
% started
statin
Average dose
(mg/day)
% reduction in
LDL cholesterol*
Assumed change in LDL
cholesterol (mmol/L){
Atorvastatin Placebo 6.1 20.5 43 21.43
Fenofibrate 2.8 21.2 44 21.33
Simvastatin Placebo 8.1 24.2 33 21.09
Fenofibrate 3.7 25.5 33 21.01
Pravastatin Placebo 2.4 28.9 26 20.87
Fenofibrate 1.4 30.0 27 20.81
Other statin Placebo 0.5 — 33 21.09
Fenofibrate 0.2 — 33 21.00
Any statin Placebo 16.1{ —— 21.18 1
Fenofibrate 7.9 — — 21.09 1
*Derived from meta-analysis of short-term randomized trials of statins [24].
{Calculated from the percentage reduction in LDL cholesterol applied to the average prior LDL cholesterol level in each treatment group for those patients who
subsequently started lipid-lowering therapy.
{93% of patients who started other lipid-lowering treatment took statins.
1Based on a weighted average of LDL change for individual statins.
FIELD=Fenofibrate Intervention and Event Lowering in Diabetes; LDL=low-density lipoprotein.
doi:10.1371/journal.pone.0008580.t003
Table 4. Assumed effects of using statins (% relative risk
reduction*) on subsequent cardiovascular (CVD) events in the
FIELD study.
Type of CVD event
Placebo
group{
Fenofibrate
group{ All patients
CHD event 27 25 26
CHD death 22 21 22
Nonfatal MI 31 28 30
CVD death 20 18 19
Stroke 20 18 19
Revascularization 28 26 27
Any CVD event 25 23 24
*Estimates of event reduction per mmol/L change in LDL cholesterol were
derived from the Cholesterol Treatment Trialists’ overview of statin therapy
[22].
{Assumed absolute change in LDL cholesterol from statin use: 21.18 mmol/L in
the placebo group and 21.09 mmol/L in the fenofibrate group.
FIELD=Fenofibrate Intervention and Event Lowering in Diabetes;
CHD=coronary heart disease; MI=myocardial infarction.
doi:10.1371/journal.pone.0008580.t004
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reduction from these treatments would apply to a broad cross-
section of patients. This appears to be the case in our example on
the basis of evidence from several randomized trials showing no
significant heterogeneity of treatment effect across a wide range of
subgroups [14,21–23].
There are several examples of placebo-controlled trials in which
the uptake of other active treatments differed by randomized
group, and where this may have contributed to an underestima-
tion of treatment effect or failure to detect a significant effect for
some outcomes. These include trials of antihypertensive therapy or
antiplatelet therapies to prevent vascular events. In trials such as
Reduction of Endpoints in NIDDM with the Angiotensin II
Antagonist Losartan (RENAAL) [33], the Study on Cognition and
Prognosis in the Elderly (SCOPE) [34], the Jikei Heart Study [35],
and Action in Diabetes and Vascular Disease (ADVANCE) [36],
the use of other antihypertensive agents was greater in the placebo
group, leading to a likely underestimation of the underlying effect
of the trial treatment, and the possibility of missing effects on some
outcomes. In the Clopidogrel in Unstable Angina to Prevent
Recurrent Events (CURE) trial [37], which evaluated clopidogrel
in acute coronary syndromes, use of thrombolytic agents and
glycoprotein IIb/IIIa inhibitors was slightly greater in the placebo
group. The effects of nontrial treatments on estimates may have
been small in some cases, but their effects can be more directly
assessed by our approach.
While we support the use of unadjusted intention-to-treat
analyses as the primary analysis in randomized trials, it should be
recognized that this may underestimate the efficacy of treatment as
applied in practice. In our example, the primary results of the
FIELD trial based on an intention-to-treat analysis of all patients
showed smaller effects of fenofibrate on cardiovascular events than
expected in the trial design. The trial was well powered to detect a
true 27% reduction in cardiovascular events, corresponding to an
approximate 22% reduction in the intention-to-treat analysis. The
observed effects of fenofibrate were substantially smaller than this,
probably in part because the average true effect of the drug is
more modest, but also because the results of the intention-to-treat
analyses were attenuated by about one-third, owing to substantial
uptake during the trial of other medicines, particularly statins,
together with the discontinuation of fenofibrate by some patients.
The adjusted analyses suggest that plausible treatment effects of
fenofibrate in this setting are a 15% reduction in all cardiovascular
disease events, a 16% reduction in major CHD events (the
primary endpoint), and 30% reduction in nonfatal CHD events,
all of which would make the value of such treatment more
Table 5. Percentages of patients using other cardiovascular drugs at baseline and study close, by randomized group, in the FIELD
study.
Baseline Baseline Study close Study close
Type of drug Placebo (n=4900) Fenofibrate (n=4895) Placebo (n=4900) Fenofibrate (n=4895)
Any antiplatelet 29 29 51 50
Aspirin 29 29 47 46
Other antiplatelet 0.6 0.3 4 4
Angiotensin-converting enzyme inhibitor 34 33 48 45
Angiotensin II receptor antagonist 5 5 20 20
Beta-blocker 14 15 26 24
Calcium antagonist 19 20 27 26
Nitrate 6 5 12 11
Diuretic 15 15 24 21
FIELD=Fenofibrate Intervention and Event Lowering in Diabetes.
doi:10.1371/journal.pone.0008580.t005
Table 6. Treatment effects of fenofibrate unadjusted and adjusted for the use of other CVD drugs in the FIELD study.
Outcome
No.
events
Unadjusted RRR
(95% CI) P
RRR adjusted for use of statins
and other CVD drugs (95% CI) P
RRR additionally adjusted for
fenofibrate discontinuation*
(95% CI) P
CHD event 544 11 (25t o2 5 ) 0 . 2 1 5( 21 to 28) 0.06 16 (21 to 31) 0.06
CHD death 203 219 (257 to 10) 0.2 214 (251 to 13) 0.3 216 (256 to 15) 0.3
Nonfatal MI 365 24 (6 to 38) 0.01 27 (10 to 41) 0.003 30 (11 to 45) 0.003
CVD death 267 211 (241 to 13) 0.4 27( 236 to 16) 0.6 28( 240 to 18) 0.6
Stroke 333 10 (212 to 27) 0.4 12 (29 to 29) 0.2 14 (210 to 33) 0.2
Revascularization 851 20 (8 to 30) 0.002 22 (11 to 32) ,0.001 25 (13 to 36) ,0.001
Any CVD event 1295 11 (1 to 20) 0.04 14 (4 to 23) 0.008 15 (4 to 25) 0.008
*Adjusted for uptake of statins and other drugs and for discontinuation of fenofibrate.
FIELD=Fenofibrate Intervention and Event Lowering in Diabetes; CVD=cardiovascular disease; RRR=relative risk reduction (%); CI=confidence interval;
CHD=coronary heart disease; MI=myocardial infarction.
doi:10.1371/journal.pone.0008580.t006
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reduction in risk of about 2% or a number needed to treat of 50
patients over 5 years to prevent a major cardiovascular disease
event. The adjusted analyses not only indicate a moderately larger
treatment effect but also provide strong statistical evidence for a
more substantial treatment effect than can be claimed using an
intention-to-treat analysis. These analyses also allow some
examination of whether the different uptakes of other cardiovas-
cular disease medicines may have been a factor in the apparent
variation in treatment effect within subgroups. Statin therapy was
more likely to be used by patients with prior cardiovascular disease
than not and by patients with more abnormal (than normal) lipid
profiles. However, adjustment for the use of statins and other
cardiovascular medicines did not appreciably alter the possible
heterogeneity for these subgroups, so this does not explain the
apparently different treatment effects. As discussed in more detail
elsewhere [1], heterogeneity across some subgroups is still
consistent with a chance finding and may relate, in part, to some
differences in other baseline characteristics.
The methods have some limitations. These include: 1. the use of
the same assumed treatment effect for each drug applied to each
individual patient; 2. the use of evidence from different settings
than might apply exactly to the trial setting of interest; and 3. the
post-hoc nature of the assumptions made in this example, such as
the source of external evidence. The post-hoc nature is not a
limitation of the method itself, as these concerns could be
addressed by building these approaches into the final analysis
plan of future trials before unblinding. Also, one could introduce
some randomness to the estimates used. In this analysis we chose
conservative assumptions or undertook sensitivity analyses of
alternative assumptions. For example, we assumed less than a fully
multiplicative model when considering multiple drugs in the same
patient, and variation in our assumptions resulted in similar
conclusions.
Further refinements to the general approach are possible by: 1.
using individual estimates of risk reduction based on a particular
drug and dose (rather than applying the average risk reduction to
all patients); and 2. considering a random variation in the size of
the treatment effect for individual patients. It is recognized that the
latter will lead to higher final P values.
Direct validation of this example in another randomized trial
will not be possible, as a trial of the same type is no longer possible.
However, it will be of interest to see, in the next 6 months, the
results of the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial [38], which is evaluating the additional effect of
fenofibrate on a background of all patients receiving statin
therapy.
Figure 3. Effects of fenofibrate on cardiovascular events, by
major subgroup. *Adjusted for use of other cardiovascular drugs and
discontinuation of fenofibrate. RRR=relative risk reduction.
doi:10.1371/journal.pone.0008580.g003
Figure 2. Effects of fenofibrate on events, with and without adjustment for use of statins and other drugs (RRR=relative risk
reduction).
doi:10.1371/journal.pone.0008580.g002
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by applying a new method that is not subject to selection bias, that
provides an estimate of the underlying treatment effect and that
takes into account both adherence to study treatment and the
differential use of other nonstudy medicines. The approach
suggests a moderate but real underestimate of the effects of
fenofibrate on the prespecified cardiovascular outcomes of the
FIELD study, which would make a stronger case for using such
therapy. The adjusted results should provide more reliable
estimates for future clinical decision making. The application of
evidence-based estimates related to the use of other nonstudy
(cardiovascular) medicines, as described in this setting, may be
relevant to many long-term clinical trials, and the approaches
adopted here should therefore have wide application and will be
especially valuable where differential changes in usual care
between treatment arms occur.
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